Marol

Tramadol hydrochloride, the active ingredient in Marol, is an opioid analgesic presented as an oral tablet for oral use. It is indicated for the management of moderate to severe pain in adult patients. GNH USA supplies Marol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tramadol is an opioid analgesic used to manage moderate to severe pain across several clinical settings.

Post‑operative pain: provides analgesia after surgical procedures. Chronic musculoskeletal pain: reduces pain intensity in conditions such as osteoarthritis. Cancer‑related pain: helps control breakthrough pain in oncology patients.

Adverse reactions may occur with tramadol use and are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness. - Constipation: reduced bowel movements. - Drowsiness: increased sleepiness. - Headache: mild to moderate head pain. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Seizures: risk increases with high doses or interacting drugs. - Respiratory depression: slowed breathing, especially in opioid‑naïve patients. - Serotonin syndrome: potentially life‑threatening when combined with serotonergic agents. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm. - Hypotension: marked drop in blood pressure.

Before prescribing tramadol, clinicians should consider several safety factors.

Assess renal function: adjust use in severe impairment. Monitor for dependence: limit duration of therapy to reduce abuse risk. Avoid in patients with seizure history: increased convulsion risk. Use caution with serotonergic drugs: potential for serotonin syndrome. Store at ambient temperature: keep in original container, protect from moisture and heat.

Tramadol may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - SSRIs or SNRIs: increased risk of serotonin syndrome. - MAO inhibitors within 14 days: severe reactions.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, alcohol): enhanced sedation. - CYP2D6 inhibitors (quinidine, fluoxetine): increased tramadol plasma levels. - Diuretics: may amplify hypotensive effects.